http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-60304309-T2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4b3db7dd56b56cc6d94d0e0cccc38322 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C235-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q5-006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61Q19-007 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K8-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C59-13 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C235-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-368 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61Q5-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K8-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C59-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-16 |
| filingDate | 2003-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2006-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188d5c25aba3c5791c1a29b970b4b1ba |
| publicationDate | 2006-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-60304309-T2 |
| titleOfInvention | Use of a (dihydro) jasmonic acid derivative for the treatment of dry skin |
| abstract | Treatment of dry skin or non-inflammatory dry scalp, particularly due to the female menopause, comprises topical application of a firming composition containing a derivative of (dihydro)jasmonic acid (I). Treatment of dry skin or non-inflammatory dry scalp, particularly due to the female menopause, comprises topical application of a firming composition containing a derivative of (dihydro)jasmonic acid of formula (I) and their isomers, stereoisomers and salts. [Image] G : C(O), CH(OR a), CH(NRR'), C=CR bR c, CH(CHR bR c), spiro ring of formula (a), C(OX)(OX') or CYY'; R aH, 1-12C aliphatic or cyclic optionally unsaturated hydrocarbyl (optionally substituted by 1-5 OR'', OC(O)R'', SR'', SC(O)R'', NR''R''', halogen, CN or C(O)OR''), C(O)R'' or C(O)R d; R'', R''' : H, aryl or 1-4C optionally unsaturated hydrocarbyl; R d1-17C alkyl, aryl, aralkyl or alkoxy (all optionally unsaturated and all optionally substituted by one or more OH or methoxy); R b, R cR or C(O)OR e; R e1-4C hydrocarbyl; R, R' : H, linear or cyclic 1-12C hydrocarbyl (optionally unsaturated and/or optionally substituted by 1-5 OR'', OC(O)R'', SR'', SC(O)R'', NR''R''', NHC(O)R'', halogen, CN or C(O)OR'') or C(O)R''; or R+R' : ring; A : 1-3C optionally unsaturated hydrocarbyl, optionally substituted by 1-6C alkyl or aryl; X, X' : 1-3C optionally unsaturated hydrocarbyl; Y, Y' : halogen; R 1C(O)OR, CH 2OR, C(O)NRR', C(O)R, CH 2R', SO 2OR, PO 3RR', NHR or NRR'; and R 21-18C linear or cyclic optionally unsaturated hydrocarbyl (optionally substituted by 1-5 OR'', OC(O)R'', SR'', SC(O)R'', NR''R''', NHC(O)R'', halogen, CN or C(O)OR'') or C(O)R''. [Image] Independent claims are also included for: (1) new (dihydro)jasmonic acid derivatives of formulae (II) and (III) and their isomers, stereoisomers and salts; (2) a skin firming composition containing (II) or (III); and (3) treatment for skincare, skin cleansing or make-up comprising topical application of a composition containing (II) or (III). [Image] G' : CH(OR aa), CH(NR yR y'), C=CR bbR cc or CH(CHR bbR cc); R aa1-12C aliphatic or cyclic optionally unsaturated hydrocarbyl (optionally substituted by 1-5 OR'', OC(O)R'', SR'', SC(O)R'', NR''R''', halogen, CN or C(O)OR''); R bb, R cc, R x, R y, R y'H or 1-12C aliphatic or cyclic optionally unsaturated hydrocarbyl (optionally substituted by 1-5 OR'', OC(O)R'', SR'', SC(O)R'', NR''R''', halogen, CN, C(O)OR'' or C(O)R''); or R y+R y' and/or R bb+R ccring; provided that, when G' = CH(NH(CH 2) 2N(CH 3) 2), then R 1 = C(O)OR and R 2 = n-pentyl. ACTIVITY : Dermatological. Human sebocytes (cell line SZ95) were immortalized by cell culture according to the method of Zouboulis et al ( J. Invest. Dermatol., 113, 1011-1020) and incubated for 48 hours with 0.001M methyl dihydrojasmonate. The cells were treated with Nile Red (1 Microg/ml) and cellular lipid concentration measured by fluorescence (485-540 nm for neutral lipids and 540-620 nm for non-neutral lipids). For samples treated with methyl dihydrojasmonate, concentration of neutral lipids synthesized in the cells was increased by 98% compared with untreated controls (p 0.001). MECHANISM OF ACTION : None given. |
| priorityDate | 2003-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.